Giovanni Guido Cerri

Giovanni Guido Cerri

Auto-generated profile, based on publicly available information

Giovanni Guido Cerri

Department of Radiology, Hospital Sirio-Libanes, Rua Adma Jafet 91, Sao Paulo, SP 01308-050, Brazil

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2020 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
FBFelipe de Galiza Barbosa
Felipe de Galiza Barbosa
MQMarcelo Araujo Queiroz
Marcelo Araujo Queiroz
RNRafael Fernandes Nunes
Rafael Fernandes Nunes
LCLarissa Bastos Costa
Larissa Bastos Costa
EZElaine Caroline Zaniboni
Elaine Caroline Zaniboni
CBCarlos Buchpiguel
Carlos Buchpiguel
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

1 October 2020 in RadioGraphics
Verified
Journal Article
Closed access
JMJosé Flávio Gomes Marin
José Flávio Gomes Marin
RNRafael F. Nunes
Rafael F. Nunes
ACArtur M. Coutinho
Artur M. Coutinho
EZElaine C. Zaniboni
Elaine C. Zaniboni
LCLarissa B. Costa
Larissa B. Costa
CBCarlos A. Buchpiguel
Carlos A. Buchpiguel
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to applications in oncology, is currently one of the greatest components of the theranostic concept in clinical and research scenarios. Theranostics in nuclear medicine, or nuclear theranostics, refers to the use of radioactive compounds to image biologic phenomena by means of expression of specific disease targets such as cell surface receptors or membrane transporters, and then to use specifically designed agents to deliver ionizing radiation to the tissues that express these targets. The nuclear theranostic approach has sparked increasing interest and gained importance in parallel to the growth in molecular imaging and personalized medicine, helping to provide customized management for various diseases; improving patient selection, prediction of response and toxicity, and determination of prognosis; and avoiding futile and costly diagnostic examinations and treatment of many diseases. The authors provide an overview of theranostic approaches in nuclear medicine, starting with a review of the main concepts and unique features of nuclear theranostics and aided by a retrospective discussion of the progress of theranostic agents since early applications, with illustrative cases emphasizing the imaging features. Advanced concepts regarding the role of fluorine 18-fluorodeoxyglucose PET in theranostics, as well as developments in and future directions of theranostics, are discussed. ©RSNA, 2020 See discussion on this article by Greenspan and Jadvar.

1 August 2020 in Radiology
Verified
Journal Article
Closed access
FCFrancisco Cesar Carnevale
Francisco Cesar Carnevale
AMAirton Mota Moreira
Airton Mota Moreira
AAAndre Moreira de Assis
Andre Moreira de Assis
AAAlberto Azoubel Antunes
Alberto Azoubel Antunes
VRVanessa Cristina de Paula Rodrigues
Vanessa Cristina de Paula Rodrigues
GCGiovanni Guido Cerri
Giovanni Guido Cerri
Prostatic artery embolization was a safe and effective treatment for men with benign prostatic hyperplasia that resulted in long-term improvements for lower urinary tract symptoms and quality of life. Background Long-term experience with prostatic artery embolization (PAE) for benign prostatic hyperplasia remains limited. Purpose To evaluate the efficacy, safety, and long-term results of PAE for...

1 January 2021 in RadioGraphics
Verified
Journal Article
Closed access
LCLarissa B. Costa
Larissa B. Costa
MQMarcelo A. Queiroz
Marcelo A. Queiroz
FBFelipe G. Barbosa
Felipe G. Barbosa
RNRafael F. Nunes
Rafael F. Nunes
EZElaine C. Zaniboni
Elaine C. Zaniboni
CBCarlos A. Buchpiguel
Carlos A. Buchpiguel
When combined with consolidated morphologic criteria, PET can play an essential role in reliably assessing response to immune checkpoint inhibitor (ICI) therapy and adverse events during immunother... Cancer demands precise evaluation and accurate and timely assessment of response to treatment. Imaging must be performed early during therapy to allow adjustments to the course of treatment. For de...

9 March 2011 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
FCFrancisco C. Carnevale
Francisco C. Carnevale
JMJoaquim Mauricio Motta-Leal-Filho
Joaquim Mauricio Motta-Leal-Filho
AAAlberto A. Antunes
Alberto A. Antunes
RBRonaldo H. Baroni
Ronaldo H. Baroni
GFGeraldo C. Freire
Geraldo C. Freire
MSMiguel Srougi
Miguel Srougi

1 September 2021 in RadioGraphics
Verified
Journal Article
Closed access
UJUbenicio Silveira Dias Jr
Ubenicio Silveira Dias Jr
MMMaurício Ruettimann Liberato de Moura
Maurício Ruettimann Liberato de Moura
PVPublio Cesar Cavalcante Viana
Publio Cesar Cavalcante Viana
AAAndré Moreira de Assis
André Moreira de Assis
AMAntônio Sérgio Zanfred Marcelino
Antônio Sérgio Zanfred Marcelino
NHNatally Horvat
Natally Horvat
Considering that the use of prostatic artery embolization to treat benign prostatic hyperplasia has been increasing, radiologists should be aware of the main technical concepts and key imaging feat... Benign prostatic hyperplasia (BPH) is a noncancerous growth of the transitional zone of the prostate, which surrounds the prostatic urethra. Consequently, it can cause lower urinary tract symptoms ...